Difference between revisions of "Actinium Ac 225 lintuzumab (Actimab-A)"
Jump to navigation
Jump to search
m (→Also know as) |
m |
||
| Line 11: | Line 11: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | |||
[[Category:Radiotherapy medications]] | [[Category:Radiotherapy medications]] | ||
| − | [[Category:Anti-CD33 | + | [[Category:Anti-CD33 radioimmunoconjugates]] |
[[Category:Acute myeloid leukemia medications (investigational)]] | [[Category:Acute myeloid leukemia medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 21:05, 30 June 2023
Mechanism of action
Monoclonal antibody directed against CD33 with a radioactive agent attached.
Preliminary data
Acute myeloid leukemia
Also known as
- Brand name: Actimab-A